{'fraction_non_alphanumeric': 0.03706030150753769, 'fraction_numerical': 0.02512562814070352, 'mean_word_length': 5.372, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Histological and urinary reactivity of monoclonal antibody 1be12 in bladder carcinoma. Purification of the antigen from urine

We have previously reported the production of monoclonal antibody (MAb) IBE 12, which recognizes a glycoprotein in breast‐cancer cells. In the present work, IBE 12 reactivity was tested by immunohistochemistry in bladder carcinoma (92 cases) and in non‐tumoral bladder samples (15 cases). In 71% of bladder tumors, more than 30% of cells were intensely stained by I BE 12. The percentage of reactive cells was higher in cancers invading the muscle than in more superficial tumors (p = 0.039). In non‐tumoral bladder, immuno‐staining, when present, was usually confined to the superficial layers with a low number of cells stained (<30%) in 13/15 cases. Slot blots, performed on urine samples from 43 bladder‐cancer patients and 21 healthy controls, were quantified by densitometry scanning. We found higher optical density (OD) values in urine from muscle‐invasive‐cancer patients than in urine from more superficial tumors and healthy controls, with a significantly different distribution (p = 0.005). The urinary antigen was detected by immunoblotting with IBE 12 as high‐molecular‐weight species (> 150 kDa). The reactive glycoprotein could thus be purified by immunoaffinity and FPLC filtration from the perchloric‐acid‐soluble fraction of urine from patients with invasive bladder carcinoma. The availability of purified antigen will allow us to quantitate our assay, in order to evaluate its potential use as a prognostic indicator in bladder‐cancer patients.